Speaker: Won-Seog Kim

0:00:51

Insights into a Phase I/II study assessing golidocitinib in PTCL

0:01:11

DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL

0:01:02

Biosimilars: making biological agents available worldwide

0:01:07

Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial

0:01:05

Key misconceptions about biosimilars

0:01:03

The importance of circulating tumor DNA in patients with primary CNS lymphoma

0:00:51

The need for novel agents for the treatment of PTCL

0:02:26

Clinical evidence supporting rituximab

0:01:12

Anbal-cel: a novel anti-CD19 CAR-T therapy with dual silencing of PD-1 & TIGIT for LBCL

0:02:09

JACKPOT8: DZD4205 in peripheral T-cell lymphoma

0:01:11

HDACIs in treating r/r PTCL

0:02:04

IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma

0:01:09

Interim analysis of anbal-cel for R/R DLBCL

0:01:35

REDIRECT results: AFM13 in patients with CD30+ R/R PTCL

0:00:42

Approaching NK/T-cell lymphoma

0:01:07

EGR1 as a prognostic biomarker in ENKTL

0:01:57

Standard of care of CAR-T therapies for B-cell malignancies

0:02:19

Anbal-cel: Updated results from Phase I study of novel CD19-targeting CAR-T therapy

0:10:23

[Indonesia-Korea Joint Seminar]_Keynote Speech_Yong-seog Kim

0:01:58

An overview on NK/T-cell lymphoma treatment

1:06:17

Novel Therapies in Aggressive Lymphoma & CAR T-cell Therapy

0:27:31

SOHO Saudi Arabia 2024 (Day 1) - Dr Abdulwahab Albabtain

0:18:39

Let us all be speakers, right now! Dongheon Han at TEDxSNU